公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Park Y.H; Senkus-Konefka E; Im S.-A; Pentheroudakis G; Saji S; Gupta S; Iwata H; Mastura M.Y; Dent R; YEN-SHEN LU ; Yin Y; Smruti B.K; Toyama T; Malwinder S; Lee S.C; Tseng L.-M; Kim J.H; Kim T.-Y; Suh K.J; Cardoso F; Yoshino T; Douillard J.-Y. | Annals of Oncology | 34 | 29 | |
2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
2018 | A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer | WEI-WU CHEN ; Yeh D.-C.; Chao T.-Y.; CHING-HUNG LIN ; Chow L.W.-C.; DWANG-YING CHANG ; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU ; Taiwan Breast Cancer Consortium | Japanese Journal of Clinical Oncology | 4 | 3 | |
2021 | A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer | YEN-SHEN LU ; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. | Clinical Cancer Research | 23 | 16 | |
2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 | |
2021 | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer | Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU ; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. | Breast Cancer Research | 17 | 15 | |
2004 | Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | YEN-SHEN LU ; Hsu C; Li C.-C; SUNG-HSIN KUO ; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. | Hepato-Gastroenterology | 14 | 13 | |
2011 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer | YEN-SHEN LU ; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO ; CHIUN-SHENG HUANG | Cancer Chemotherapy and Pharmacology | 10 | 8 | |
2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |
2002 | Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma | CHIUN HSU ; CHIUN-SHENG HUANG ; Chao T.-Y.; YEN-SHEN LU ; Bu C.-F.; Chen M.M.; KING-JEN CHANG ; ANN-LII CHENG | Cancer | 12 | 11 | |
2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
2017 | Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen | I-CHUN CHEN ; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; CHING-HUNG LIN ; Wei-Wu Chen T.; ANN-LII CHENG ; YEN-SHEN LU | Scientific Reports | 23 | 20 | |
2013 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas | Wu P.-F.; Huang W.-C.; CHIH-HSIN YANG ; YEN-SHEN LU ; JIN-YUAN SHIH ; SHANG-GIN WU ; CHING-HUNG LIN ; ANN-LII CHENG | Journal of Neuro-Oncology | 8 | 5 | |
2019 | PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study | MING-HAN YANG ; I-CHUN CHEN ; YEN-SHEN LU | Journal of the Formosan Medical Association | 21 | 17 | |
2015 | A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis | Wu P.-F.; CHING-HUNG LIN ; CHING-HUA KUO ; WEI-WU CHEN ; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU | BMC Cancer | 48 | 36 | |
2016 | A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer | BANG-BIN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; WEI-WU CHEN ; Wu P.-F.; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | BMC Cancer | 20 | 17 | |
2023 | Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer | WEI-WU CHEN ; Hsiao, Wen; Dai, Ming-Shen; CHING-HUNG LIN ; DWANG-YING CHANG ; I-CHUN CHEN ; MING-YANG WANG ; Chang, Shu-Han; Huang, Shu-Min; ANN-LII CHENG ; Wu, Ko-Wen; Tan, Kien Thiam; YEN-SHEN LU | Breast cancer research and treatment | 0 | 0 | |